"Pyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
| Descriptor ID |
D011725
|
| MeSH Number(s) |
D03.383.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridines".
Below are MeSH descriptors whose meaning is more specific than "Pyridines".
This graph shows the total number of publications written about "Pyridines" by people in this website by year, and whether "Pyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 3 | 3 | 6 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 2 | 4 |
| 2010 | 1 | 2 | 3 |
| 2011 | 5 | 0 | 5 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 3 | 5 |
| 2015 | 3 | 0 | 3 |
| 2016 | 5 | 0 | 5 |
| 2017 | 5 | 1 | 6 |
| 2018 | 4 | 3 | 7 |
| 2019 | 1 | 3 | 4 |
| 2020 | 3 | 1 | 4 |
| 2021 | 2 | 4 | 6 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridines" by people in Profiles.
-
Synthesis of 3-N-/O-/S-methyl-imidazo[1,2-a] pyridine derivatives for caspase-3 mediated apoptosis induced anticancer activity. Bioorg Chem. 2022 08; 125:105882.
-
Evaluating the Response of Palbociclib on Progression-Free Survival in Hormone Receptor-Positive Metastatic Breast Cancer. Oncology. 2022; 100(6):337-343.
-
Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. J Thromb Haemost. 2021 12; 19(12):3008-3017.
-
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. N Engl J Med. 2021 12 02; 385(23):2150-2160.
-
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021 05 15; 27(10):2734-2741.
-
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. Ann Oncol. 2021 06; 32(6):817-819.
-
Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era. Semin Respir Crit Care Med. 2021 04; 42(2):308-315.
-
Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clin Cancer Res. 2021 04 01; 27(7):1864-1874.
-
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2021 02; 32(2):261-268.
-
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study. J Am Heart Assoc. 2020 04 21; 9(8):e015865.